(Bloomberg) -- Drugmaker Grifols SA and US short seller Gotham City Research are counting on two different reports from a Spanish regulator to bolster their cases as they prepare to face off in ...

Grifols has filed for US approval of a new drug for rare bleeding disorder acquired fibrinogen deficiency (AFD), which promises to provide a more reliable and easier treatment for patients.

‘Chronos-PD’ is looking for biological signals that could indicate increased chance of developing Parkinson’s disease (PD) years before symptoms appear, leading to new diagnostic tools and ...

Private equity company Brookfield has reportedly moved closer to taking control of Grifols, after months of disruption at the Spanish pharma company. A report in Spanish newspaper El Confidencial ...

John Sacaria Thirusailam, once very active in life, was forced to leave his well-paid job at the age of 44 after being ...

Rigel Pharmaceuticals, Inc. RIGL is set to report its fourth-quarter and full-year 2024 earnings on March 4. The Zacks ...

Bank stocks led European equities traded in the US as American depositary receipts higher late Tuesday morning, rising 0.80% to 1,418.65 on the S&P Europe Select ADR Index. From continental Europe, ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Market Drivers: Key drivers include increasing prevalence of immunodeficiency disorders globally, rising demand for plasma-derived medicinal products, and a growing geriatric population. The market ...

GRIFOLS transfer bags are used for sterile preservation and administration of blood components. Blood components can be obtained, stored and preserved without contact with the environment ensuring ...

After hours: February 21 at 4:53:23 PM EST ...